Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURA: Abemaciclib for locoregional recurrence of breast cancer
NCT07190443Phase 3Recruiting
- Sponsor
- Japanese Foundation for Cancer Research
- Start
- Feb 2025
- Primary completion
- Feb 2034
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib in breast cancer, sponsored by Japanese Foundation for Cancer Research. Started Feb 2025; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07190443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190443.